NASDAQ NMS - GLOBAL MARKET · ANIP
+0.07% · +$0.0500 · Vol 419.7K
Market closed · last close 4:00 PM ET · price as of 16:01:07 ET
ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Pharmaceuticals
$71.98
Card
Relationship Map

Follow $ANIP

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ANIP by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
ANIP
ANI Pharmaceuticals Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

74/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ANIP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ANIP catalysts
About ANI Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
1999
Employees
970
Country
US

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$71.84
Day high
$73.01
Day low
$71.28
Previous close
$71.93
52W high
$95.38
-24.53% from high
52W low
$70.19
7% of range
Market cap
$1.7B
P/E
15.25×
EPS
$5.00
Beta
-0.23
Shares out
23M
Volume
419.7K
1.05× rel vol
Avg volume
399.4K
VWAP
$72.12
Price history computed in-house
1W
-0.28%
1M
+1.81%
3M
-12.29%
1Y
-20.71%
YTD
-8.82%
SMA 50 $74.70 · below
SMA 200 $78.31 · below
52W position 7%

ANIP overview

Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file
Loading financial statements
Loading ANIP Form 4 filings
Public disclosures

Congress activity in ANIP

No receipt-qualified filings found.

Federal contracts

ANIP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ANIP in this window.
Lobbying spend

ANIP lobbying filings, year to date.

Registered lobbying filings matched to ANI Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ANIP in this window.
Loading news for ANIP
Analyst ratings
Sovereign unlock shows live analyst consensus for ANIP.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.